CMND - Why Psychedelic-Pharma Clearmind Medicine Stock Is Moving Higher | Benzinga
Clearmind Medicine Inc. (NASDAQ:CMND) shares are trading higher Friday after the company announced advancement in its proprietary MEAI-based binge behavior regulator program through the granting of patent approval in Hong Kong by the Hong Kong Patent Office.
The Details:
Clearmind said the allowed claims are directed to use a primary amine aminoindan compound to regulate binge behavior, including primary amine aminoindan compounds beyond 5-methoxy-2-aminoindan (MEAI), the company’s innovative psychedelic molecule.
MEAI is a psychoactive molecule that reduces the desire to consume alcoholic beverages and provides a slight euphoric, alcohol-like experience. Clearmind’s MEAI-based flagship treatment focuses on Alcohol Use Disorder and weight loss. MEAI may also be used to treat binge drinking, according to Clearmind.
The company has 28 granted patents across 18 patent families, with patents granted in major jurisdictions such as the U.S., Europe, China, India and ...